ARGENX SE (ARGX.BR) Stock Price, Forecast & Analysis
EBR:ARGX • NL0010832176
ARGX.BR Key Statistics, Chart & Performance
The current stock price of ARGX.BR is 710.2 EUR. In the past year, price increased by 18.92%.
ARGX.BR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR turns out to be only a medium performer in the overall market: it outperformed 50.64% of all stocks.
ARGX.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR. ARGX.BR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
ARGX.BR Financial Highlights
Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 10.55. The EPS increased by 1512.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.97% | ||
| ROA | 17.84% | ||
| ROE | 21% | ||
| Debt/Equity | 0.01 |
ARGX.BR Forecast & Estimates
25 analysts have analysed ARGX.BR and the average price target is 876.91 EUR. This implies a price increase of 23.47% is expected in the next year compared to the current price of 710.2.
For the next year, analysts expect an EPS growth of 934.93% and a revenue growth 95.19% for ARGX.BR
ARGX.BR Ownership
ARGX.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.89 | 43.962B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.579B | ||
| ABVX | ABIVAX SA | N/A | 8.651B | ||
| 2X1 | ABIVAX SA | N/A | 8.619B | ||
| GXE | GALAPAGOS NV | N/A | 1.957B | ||
| GLPG | GALAPAGOS NV | N/A | 1.948B | ||
| IVA | INVENTIVA SA | N/A | 1.18B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| NANO | NANOBIOTIX | N/A | 1.048B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ARGX.BR
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1599
Phone: 31763030
ARGENX SE / ARGX.BR FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
What is the current price of ARGX stock?
The current stock price of ARGX.BR is 710.2 EUR. The price increased by 0.14% in the last trading session.
What is the dividend status of ARGENX SE?
ARGX.BR does not pay a dividend.
What is the ChartMill rating of ARGENX SE stock?
ARGX.BR has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for ARGX.BR stock?
25 analysts have analysed ARGX.BR and the average price target is 876.91 EUR. This implies a price increase of 23.47% is expected in the next year compared to the current price of 710.2.
How is the valuation of ARGENX SE (ARGX.BR) based on its PE ratio?
The PE ratio for ARGENX SE (ARGX.BR) is 67.32. This is based on the reported non-GAAP earnings per share of 10.55 and the current share price of 710.2 EUR.
Can you provide the market cap for ARGENX SE?
ARGENX SE (ARGX.BR) has a market capitalization of 43.95B EUR. This makes ARGX.BR a Large Cap stock.